Testing a new drug for high-risk bladder cancer that came back after BCG
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This clinical trial tests a new drug, BH011, for people with high-risk, non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. The goal is to see if the drug is safe and works well when given directly into the bladder, as an alternative to bladder removal surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have a type of bladder cancer that hasn't spread into the bladder muscle (non-muscle-invasive) and is considered high-risk.
- You have already tried BCG therapy (a treatment placed inside the bladder) and it didn't work or you couldn't tolerate it.
- You had surgery (TURBT) to remove the tumor within the past 12 weeks, and doctors confirmed all visible cancer was removed.
- You are well enough to be up and active (ECOG score 0–1) and have good blood counts, liver function, and kidney function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two treatments after bladder tumor surgery: a drug called toripalimab (given through a vein) plus BCG therapy (given into the bladder) for people with high-risk non-muscle-invasive bladder cancer. The goal is to see if this combination can help prevent the cancer from coming back.
This trial studies a BCG-based bladder instillation in people with newly diagnosed, intermediate- or high-risk non-muscle invasive bladder cancer who have had their tumor fully removed. The goal is to see whether this treatment is safer and works better to lower the chance of the cancer coming back.
This trial tests a new drug called 9MW2821 for people with high-risk bladder cancer that hasn't grown into the bladder muscle. It's for those who have already tried other treatments that didn't work or who can't have standard therapy.
This trial tests if a special type of tumor removal (ERBT) followed by BCG immunotherapy is better than standard treatment for medium- or high-risk non-muscle-invasive bladder cancer. It may help people whose bladder cancer has come back, has multiple tumors, or has a tumor larger than 1 cm.
This trial tests whether radiation therapy can help people whose bladder cancer (specifically carcinoma in situ) did not get better with BCG treatment and who are not having their bladder removed. It aims to offer a less invasive option for controlling the cancer.
This trial tests a new drug (FL115) given directly into the bladder, alone or with BCG, for people with a type of bladder cancer that has not responded to BCG therapy. It aims to find a better treatment option for those who cannot have or refuse bladder removal surgery.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.